Analyst Price Target Update on TherapeuticsMD (NYSEMKT:TXMD)

TherapeuticsMD (NYSEMKT:TXMD) should head towards $15.63 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $13 per share. The higher price estimate target is at $18 according to the Analysts.

Many analysts have stated their opinion on the company shares. Goldman Sachs initiates coverage on TherapeuticsMD (NYSEMKT:TXMD) In a research note issued to the investors, the brokerage major announces price-target of $10 per share.The shares have been rated Buy. The rating by the firm was issued on April 4, 2016. For the current week, the company shares have a recommendation consensus of Buy.

On the companys insider trading activities, Collins Cooper C., director of Therapeuticsmd, Inc., executed a transaction worth $99,680 on March 11, 2016. A total of 16,000 shares were purchased at an average price of $6.23. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

TherapeuticsMD (NYSEMKT:TXMD) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.23 points or 2.61% at $8.58 with 859,236 shares getting traded. Post opening the session at $8.78, the shares hit an intraday low of $8.58 and an intraday high of $9.05 and the price was in this range throughout the day. The company has a market cap of $1,684 million and the number of outstanding shares have been calculated to be 196,263,700 shares. The 52-week high of TherapeuticsMD (NYSEMKT:TXMD) is $11.26 and the 52-week low is $5.18.

TherapeuticsMD, Inc. is a womens health care product company. The Company is engaged in creating and commercializing products for women. The Company is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins. It markets its prescription and OTC prenatal vitamins and other products under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, also referred to as generic formulations, under its BocaGreenMD brand name. The Companys products include prenatal vitamins, vitaMedMD Plus Rx, vitaMedMD One Rx, vitaMedMD RediChew Rx and BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were generic formulations of its vitaMedMD-branded prescription prenatal vitamins.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.